Lorlatinib/lorlatinib resistance time

Lorlatinib/lorlatinib (Lorlatinib) is a targeted drug used to treat ALK (Anaplastic Lymphoma Kinase)-positive non-small cell lung cancer (NSCLC). Drug resistance means that tumor cells become resistant to drugs, causing the drugs to lose their efficacy. At present, more research and data support are needed on the resistance time of lorlatinib, because the efficacy and resistance of the drug may vary due to individual differences, disease progression, treatment regimen and other factors.

However, studies have shown that during the treatment of NSCLC with lorlatinibtumor cells often gradually develop resistance to the drug. This is due to the ability of tumor cells to undergo genetic variation and adaptive mutations. Therefore, as treatment progresses, the efficacy of lorlatinib may gradually decrease, and patients' tumors may develop drug resistance.

In a clinical study of lorlatinib, the majority of patients (85%) received lotinib in third or higher lines, with a median time to treatment discontinuation (TTD) of 8.5 months and a median time to progression (TTP) of 6.8 months, which is consistent with the known efficacy of lorlatinib in this patient population in phase 2 trials. Among 21 patients with known baseline ALK mutation status pre-lorlatinib biopsy, patients with known baseline ALK mutations in tumors ( pre-lorlatinib ) TTP and TTD were significantly longer than those in patients with unknown baseline ALK mutation (TTP: 7.8 months vs 2.8 months, HR0.363, TTD: 13.5 months vs 4.1 months, HR0.128), again consistent with the phase 2 trial results.

Researchers are working to explore and understand the mechanisms of resistance to lorlatinib and find ways to combat resistance. In their research, they are also trying to discover biomarkers associated with resistance so that they can predict a patient's response to the drug and the risk of developing resistance. Most importantly, patients should be monitored and evaluated regularly while receiving lorlatinib to detect early signs of resistance. If resistance develops, doctors can choose other treatment options based on the patient's condition, such as combinations, alternative targeted drugs, or other treatment strategies.